Century Therapeutics Inc. (IPSC) NASDAQ
$2.96 (0.17) (-5.43%)
Market Cap: $202.88M
As of 04/24/24 04:00 PM EDT. Market closed.
Century Therapeutics Inc. (IPSC)
NASDAQ
$2.96
(0.17) (-5.43%)
Market Cap: $202.88M
As of 04/24/24 04:00 PM EDT. Market closed.
Add to Portfolio
Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Lalo Flores
Full Time Employees
102
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Lalo Flores
Full Time Employees
102
Address
3675 Market Street, PA, Philadelphia, 19104.
PRICE CHART FOR CENTURY THERAPEUTICS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.22
Previous Close
$3.13
Days Range
$3.09 - $3.44
52 week range
$1.28 - $5.51
Volume
134,089
Avg. Volume (30 days)
130,361
Market Cap
$202.88M
Dividend Yield
-
P/E
(1.48)
Shares Outstanding
64,817,863
Open
$3.22
Previous Close
$3.13
Days Range
$3.09 - $3.44
52 week range
$1.28 - $5.51
Volume
134,089
Avg. Volume (30 days)
130,361
Market Cap
$202.88M
Dividend Yield
-
P/E
(1.48)
Shares Outstanding
64,817,863
FINANCIAL STATEMENTS FOR CENTURY THERAPEUTICS INC
LOADING...
INSIDER TRANSACTIONS FOR CENTURY THERAPEUTICS INC
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Russotti Gregory | See Remarks | Apr 22, 2024 | Sale | $3.10 | 5,000 | 15,489 | 297,319 | Apr 24, 2024, 04:17 PM |
Farid Adrienne | Chief Operations Officer | Mar 07, 2024 | Option Exercise | $1.03 | 22,831 | 23,516 | 136,980 | Mar 08, 2024, 06:29 PM |
Farid Adrienne | Chief Operations Officer | Mar 06, 2024 | Option Exercise | $1.03 | 30,684 | 31,605 | 144,833 | Mar 08, 2024, 06:29 PM |
Farid Adrienne | Chief Operations Officer | Mar 07, 2024 | Sale | $5.14 | 22,831 | 117,342 | 114,149 | Mar 08, 2024, 06:29 PM |
Farid Adrienne | Chief Operations Officer | Mar 06, 2024 | Sale | $4.96 | 30,684 | 152,340 | 114,149 | Mar 08, 2024, 06:29 PM |
Farid Adrienne | Chief Operations Officer | Feb 16, 2024 | Option Exercise | $1.03 | 485 | 500 | 114,634 | Feb 21, 2024, 04:10 PM |
Farid Adrienne | Chief Operations Officer | Feb 16, 2024 | Sale | $4.86 | 485 | 2,358 | 114,149 | Feb 21, 2024, 04:10 PM |
Carr Douglas | SVP Finance & Operations | Feb 06, 2024 | Sale | $4.49 | 557 | 2,499 | 303,580 | Feb 07, 2024, 05:21 PM |
Carr Douglas | SVP Finance & Operations | Feb 05, 2024 | Sale | $3.84 | 643 | 2,470 | 304,137 | Feb 07, 2024, 05:21 PM |
Farid Adrienne | Chief Operations Officer | Feb 06, 2024 | Sale | $4.49 | 1,784 | 8,005 | 114,149 | Feb 07, 2024, 05:21 PM |
Farid Adrienne | Chief Operations Officer | Feb 05, 2024 | Sale | $3.84 | 2,035 | 7,816 | 115,933 | Feb 07, 2024, 05:21 PM |
Carr Douglas | SVP Finance & Operations | Nov 01, 2023 | Option Exercise | $1.49 | 16,611 | 24,750 | 304,780 | Nov 03, 2023, 04:04 PM |
Diem Michael Craig | Chief Financial Officer | Nov 01, 2023 | Option Exercise | $1.49 | 20,763 | 30,937 | 253,533 | Nov 03, 2023, 04:04 PM |
Borges Luis | Chief Scientific Officer | Apr 03, 2023 | Option Exercise | $1.03 | 7,452 | 7,676 | 256,535 | Apr 05, 2023, 04:27 PM |
Borges Luis | Chief Scientific Officer | Mar 21, 2023 | Option Exercise | $1.03 | 63,616 | 65,524 | 107,366 | Mar 23, 2023, 07:31 PM |
Borges Luis | Chief Scientific Officer | Mar 23, 2023 | Option Exercise | $1.03 | 220,930 | 227,558 | 264,680 | Mar 23, 2023, 07:31 PM |
Borges Luis | Chief Scientific Officer | Mar 22, 2023 | Option Exercise | $1.03 | 65,698 | 67,669 | 109,448 | Mar 23, 2023, 07:31 PM |
Borges Luis | Chief Scientific Officer | Mar 23, 2023 | Sale | $3.55 | 15,597 | 55,369 | 249,083 | Mar 23, 2023, 07:31 PM |
Borges Luis | Chief Scientific Officer | Mar 22, 2023 | Sale | $3.72 | 65,698 | 244,640 | 43,750 | Mar 23, 2023, 07:31 PM |
Borges Luis | Chief Scientific Officer | Mar 21, 2023 | Sale | $3.77 | 63,616 | 239,870 | 43,750 | Mar 23, 2023, 07:31 PM |
Versant Venture Capital VI, L.P. | 10% Owner | Aug 09, 2022 | Sale | $13.03 | 550,000 | 7,166,610 | 11,816,814 | Aug 11, 2022, 04:55 PM |
BAYER AKTIENGESELLSCHAFT | 10% Owner | Jun 22, 2021 | Buy | $20.00 | 750,000 | 15,000,000 | 12,675,838 | Jun 23, 2021, 04:41 PM |
Versant Venture Capital VI, L.P. | 10% Owner | Jun 22, 2021 | Buy | $20.00 | 100,000 | 2,000,000 | 714,095 | Jun 23, 2021, 04:30 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
Owner | Relationship | Date | Value($) |
Russotti Gregory | See Remarks | 04/22/2024 | 15,489 |
Farid Adrienne | Chief Operations Officer | 03/07/2024 | 23,516 |
Farid Adrienne | Chief Operations Officer | 03/06/2024 | 31,605 |
Farid Adrienne | Chief Operations Officer | 03/07/2024 | 117,342 |
Farid Adrienne | Chief Operations Officer | 03/06/2024 | 152,340 |
Farid Adrienne | Chief Operations Officer | 02/16/2024 | 500 |
Farid Adrienne | Chief Operations Officer | 02/16/2024 | 2,358 |
Carr Douglas | SVP Finance & Operations | 02/06/2024 | 2,499 |
Carr Douglas | SVP Finance & Operations | 02/05/2024 | 2,470 |
Farid Adrienne | Chief Operations Officer | 02/06/2024 | 8,005 |
Farid Adrienne | Chief Operations Officer | 02/05/2024 | 7,816 |
Carr Douglas | SVP Finance & Operations | 11/01/2023 | 24,750 |
Diem Michael Craig | Chief Financial Officer | 11/01/2023 | 30,937 |
Borges Luis | Chief Scientific Officer | 04/03/2023 | 7,676 |
Borges Luis | Chief Scientific Officer | 03/21/2023 | 65,524 |
Borges Luis | Chief Scientific Officer | 03/23/2023 | 227,558 |
Borges Luis | Chief Scientific Officer | 03/22/2023 | 67,669 |
Borges Luis | Chief Scientific Officer | 03/23/2023 | 55,369 |
Borges Luis | Chief Scientific Officer | 03/22/2023 | 244,640 |
Borges Luis | Chief Scientific Officer | 03/21/2023 | 239,870 |
Versant Venture Capital VI, L.P. | 10% Owner | 08/09/2022 | 7,166,610 |
BAYER AKTIENGESELLSCHAFT | 10% Owner | 06/22/2021 | 15,000,000 |
Versant Venture Capital VI, L.P. | 10% Owner | 06/22/2021 | 2,000,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN CENTURY THERAPEUTICS INC
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 1,518,996 | 0.00013% | -4.77% | Other |
BAKER BROS. ADVISORS LP | 797,460 | 0.03% | -30.62% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 468,457 | 0.00016% | 0.81% | Other |
RENAISSANCE TECHNOLOGIES LLC | 119,200 | 0.00061% | 35.92% | Other |
CHANGE IN SHARES OUTSTANDING FOR CENTURY THERAPEUTICS INC
STOCK BUYBACKS FOR CENTURY THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 12/31/2023
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
09/30/2023
0.92%
1Q
06/30/2023
1.26%
2Q
03/31/2023
2.36%
3Q
12/31/2022
2.90%
4Q
09/30/2022
3.49%
5Q
06/30/2022
4.01%
6Q
03/31/2022
5.16%
7Q
12/31/2021
85.21%
8Q
09/30/2021
10.14%
9Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR CENTURY THERAPEUTICS INC
LOADING...